News Quantified

CTMX – cytomx therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Barclays PLC.

CytomX Therapeutics (NASDAQ:CTMX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.

CytomX Therapeutics (NASDAQ:CTMX) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.

CytomX Therapeutics Announces Business Update and Company Milestones for 2026

Piper Sandler and H.C. Wainwright Stay Bullish on CytomX (CTMX) [Yahoo! Finance]

-8.4%

MISS

5.4%

BEAT

71.8%

BEAT

Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Venrock Healthcare Capital Partners III, L.P.

Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Point72 Asset Management, L.P.

Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: Seven Fleet Capital Management LP

Form 4 CytomX Therapeutics, For: Nov 06 Filed by: McCarthy Sean A.

Form SCHEDULE 13G/A CytomX Therapeutics, Filed by: FMR LLC

Top News Gainers

3/23 CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER 32.5%

3/16 CytomX Therapeutics Announces New Employment Inducement Grant 27.7%

4/28 CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors 25.3%

11/19 CytomX Therapeutics Inc (NASDAQ: CTMX) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock. 15.1%

3/30 CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline 14.5%

5/9 Form 10-Q CytomX Therapeutics, For: Mar 31 11.0%

7/9 CytomX Therapeutics Announces Second Target Selection and Program Initiation with AbbVie Under Ongoing, Multi-Program Strategic Oncology Collaboration 9.3%

2/7 CytomX Therapeutics Announces New Employment Inducement Grant 8.6%

12/19 CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook 8.4%

8/6 CytomX Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference 8.4%

Top News Decliners

3/6 Form SC 13G CytomX Therapeutics, Filed by: BIOTECHNOLOGY VALUE FUND L P -11.6%

4/30 CytomX Therapeutics Inc (NASDAQ: CTMX) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $16.00 price target on the stock. -8.3%

5/29 Form 8-K CytomX Therapeutics, For: May 22 -8.2%

8/8 CytomX Therapeutics Inc (NASDAQ: CTMX) had its "buy" rating re-affirmed by analysts at Cowen Inc. -7.6%

10/24 CytomX Therapeutics to Announce Third Quarter 2019 Financial Results -6.9%

11/11 CytomX Therapeutics Inc (NASDAQ: CTMX) was downgraded by analysts at Wedbush from an "outperform" rating to a "neutral" rating. They now have a $8.00 price target on the stock, down previously from $25.00. -6.7%

2/28 CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q4 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.1%

6/21 Form 8-K/A CytomX Therapeutics, For: Dec 19 -5.7%

8/22 Form 8-K CytomX Therapeutics, For: Aug 19 -4.3%

8/27 CytomX Therapeutics Inc (NASDAQ: CTMX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day